First report of ibrutinib in IgM-related amyloidosis: few responses, poor tolerability, and short survival
2017; Elsevier BV; Volume: 131; Issue: 3 Linguagem: Inglês
10.1182/blood-2017-09-806463
ISSN1528-0020
AutoresTomáš Pika, Ute Hegenbart, Pavla Flodrová, Bettina Maier, Christoph Kimmich, Stefan Schönland,
Tópico(s)Chronic Myeloid Leukemia Treatments
Referência(s)